anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A Virtual Patient Care (VPC) platform establishes a video call between a patient application and a clinician application. During the video call Selfie Vitals are measured using the selfie camera on the patient's smartphone. The patient's video is paused to the clinician and sent to Artificial Intelligence (AI) engines using remote Photoplethysmography (rPPG) or Transdermal Optical Imaging (TOI) techniques to extract vital signs. Pulse, blood pressure, oxygen saturation, and respiration rate vital signs are generated and displayed on the clinician' s user interface. Audio continues while video conferencing may be paused during vitals measurement. The patient's smartphone can perform pre-processing to generate metadata that is sent to a VPC server with more powerful AI engines. Vitals measurement can be initiated by the patient selecting a Selfie Vitals icon on a patient user interface during the video conference call or can be initiated by the clinician.
AZACTAM may be administered intravenously or by intramuscular injection. Dosage and route of administration should be determined by susceptibility of the causative organisms, severity and site of infection, and the condition of the patient.

Because of the serious nature of infections due to Pseudomonas aeruginosa, dosage of 2 g every six or eight hours is recommended, at least upon initiation of therapy, in systemic infections caused by this organism.

The intravenous route is recommended for patients requiring single doses greater than 1 g or those with bacterial septicemia, localized parenchymal abscess (eg, intra-abdominal abscess), peritonitis, or other severe systemic or life-threatening infections.

The duration of therapy depends on the severity of infection. Generally, AZACTAM should be continued for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. Persistent infections may require treatment for several weeks. Doses smaller than those indicated should not be used.
Infliximab, a murine chimeric monoclonal antibody targeted against TNF-alpha has recently been licensed for the treatment of adult patients with established rheumatoid arthritis (RA). A double blind placebo controlled trial in children with juvenile rheumatoid arthritis (JRA) using a single dose fixed infusion regimen is currently ongoing. This dose finding study is designed to determine whether a clinically guided intravenous (iv) infusion regimen allowing for intra-patient dose escalation is superior in achieving a 70% clinical response to fixed dose administration of infliximab in children with a polyarticular course of JRA. We will model the pharmacokinetic profile in both phases of the study. We plan to enroll a maximum of 48 patients to allow for 36 patients to be randomized into the two treatment arms. In the first phase of the study all patients will receive a fixed dose of 5mg/kg/dose for a total of 3 infusions over 6 weeks (weeks 0, 2, 6). In the second phase at week 14, patients who have not achieved a 70% improvement will be randomized at a 2:1 ratio to either receive intra-patient dose escalation capped at 15mg/kg/dose every 8 weeks or continue to receive 5mg/kg/dose every 8 weeks in a blinded fashion. After 6 additional IV doses, patients will again be evaluated clinically, radiographically and serologically for clinical response. Patients who achieved a 70% response by week 14 will be kept on 5mg/kg/dose every 8 weeks for the trial duration of 62 weeks, but will not be included in the primary endpoint analysis. We also plan to evaluate patients endocrinologically and metabolically to determine the effect of TNF blockade on these systems.
BACKGROUND: Headache is among the most common symptoms following concussion, yet headache after concussion (HAC) remains poorly characterized. This study describes headache characteristics over the first four weeks following pediatric sport-related concussion.
METHODS: This is a retrospective case series of 87 athletes (mean: 14.9 years; range: 8.4-18.8 years; 38% female) treated in a specialty sports concussion clinic within 28 days of injury. Primary outcomes of headache consistency, frequency, duration, and associated migrainous symptoms were assessed at immediate (0 to 48 h) and weekly time points over the first 28 days post-injury. Generalized mixed linear models compared headache characteristics across time points. Secondary analyses compared each outcome by as-needed analgesic use.
RESULTS: During the immediate post-injury period, headache was more often constant (p = 0.002) and associated with migrainous symptoms (p < 0.001). By the third week post-injury, episodic headache was more prevalent (p < 0.001). Most patients (54%) transitioned from constant, migrainous headache to episodic, non-migrainous headache. This finding was uninfluenced by as-needed analgesic medication use.
CONCLUSIONS: These findings document the trajectory of HAC. Future studies should assess relationships between initial headache characteristics and recovery.
PURPOSE:To obtain a rough composition having soft feeling and giving moisture and low irritation to the lip, by using a vegetable oil having a specific iodine value, a specific ultraviolet absorbent and a specific antioxidant as essential components. CONSTITUTION:The objective rouge composition contains 5-25wt.% vegetable oil having an iodine value of 60-180 (e.g. safflower oil, sesame oil, castor oil, etc.), 0.001-3% one or more ultraviolet absorbents of formula I [R is -C(CH3) or -OCH3], formula (R is CnH2n+1; n is 2-10) or formula III (one or two of R1-R3 are group of formula IV and the other is group of formula V) and 0.01-2% antioxidant selected from tocopherols, flavone derivative, gallic acid derivative and extract of Rumex japonicus (a plant of Polygonaceae family). The ultraviolet absorber in the composition acts as an adjuvant of the antioxidant to remarkably suppress the degradation of the vegetable oil. Accordingly, the change in odor and color of rouge and the irritation to the lip can be suppressed.
The XEN1101 Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled, multicenter study with an optional open-label extension (OLE) to evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy. Approximately 300 patients will be randomized in a blinded manner to one of three active treatment groups or placebo in a 2:1:1:2 fashion (XEN1101 25 mg : 20 mg : 10 mg : Placebo). After screening, patients will have 8 weeks of baseline to assess frequency of seizures, followed by 8 weeks of treatment and a 6-week post treatment follow-up period. In order to be included in the study, patients must already be treated with a stable dose of 1 to 3 allowable current anti-epileptic drugs for at least one month prior to screening, during baseline, and throughout the double-blind portion (DBP) of the study. During the treatment period, patients will be given XEN1101 or placebo once daily in the evening. An OLE will be available to eligible patients who complete the DBP. All patients will receive a 20 mg daily dose of XEN1101 during this extension period.
BACKGROUND: Observational studies have shown a link between autoimmune diseases and schizophrenia, with conflicting conclusions. Due to the existence of confounding factors, the causal link between autoimmune diseases and schizophrenia is still unknown.
METHOD: We conducted a comprehensive Mendelian randomization (MR) analysis of schizophrenia and ten common autoimmune diseases in individuals of European descent using genome-wide association studies (GWASs). To evaluate the relationships between autoimmune diseases and schizophrenia, inverse variance weighted, MR-RAPS, Bayesian weighted MR, constrained maximum likelihood, debiased IVW, MR-Egger, and weighted median were utilized. Several sensitivity analyses were performed to ensure the reliability of the study's results.
RESULTS: Our findings reveal that genetically predicted ankylosing spondylitis is related to an increased risk of schizophrenia, whereas celiac disease, type 1 diabetes, and systemic lupus erythematosus are associated with a lower risk of schizophrenia. In the reverse MR analysis, our study indicated that genetically predicted schizophrenia is linked to higher risks of ankylosing spondylitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, and psoriasis. Neither multiple sclerosis nor rheumatoid arthritis have been linked to schizophrenia, and vice versa.
CONCLUSION: Despite contradicting some other observational reports, this study showed support for a causal link between autoimmune diseases and schizophrenia. To gain a better understanding of the mechanisms underlying the development of immune-mediated schizophrenia, additional research is required to identify potential mechanisms identified in observational studies.
This was a retrospective study. 45 patients who had hospital based cardiopulmonary rehabilitation programme between January and July 2023, in our rehabilitation clinic.
All participants will receive 9 sessions of Emotion Regulation Training delivered via telehealth. These individualized therapy sessions are 1-hour in length and occur semi-weekly over the course of four weeks.
This study was designed to test the laxative effects of two fibers a resistant starch made from corn and a glucose polymer fiber. The secondary aim of this study was to examine the satieting effects of these fibers. This trial was double-blind and placebo controlled. On the first day of the study subjects consumed the breakfast cereal and milk and were instructed to complete visual analog scales periodically to test acute satiety. Subjects also completed diet records and tolerance questionnaires on days 1,2, and 10. Additionally subjects completed another satiety survey on day 10 to test chronic satiety. Whole gut transit time, fecal weight, and fecal chemistry was tested by swallowing radioopaque pellets on day 6 and collecting every fecal sample for the 5 days thereafter.
In a meta-study, we evaluated the effectiveness and security of the combination of topical anaesthetic and dexmedetomidine in the treatment of postoperative pain in patients with lumbar disease. Four databases were systematically searched for possible related articles. Only English-language research was taken into account on the Internet. Furthermore, we only took into account the studies that were published prior to 2023. Only those that fulfilled the eligibility criteria were considered: (1) in adults who were about to undergo spine operation, (2) dexmedetomidine combined with local anaesthesia, (3) Visual Analog Scale scores at 4 and 24 h after the event and (4) this was a randomized or nonrandomized, controlled study. The meta-analysis was carried out with Revman 5.3 software. A ROBINS-I-based instrument was used to evaluate controlled studies. All trials were synthesized by computing the end results with either a fixed or a random effect model, which was dependent on statistical diversity. Five trials showed a marked reduction in wound pain at 4 h after the operation in patients who were treated with dexmedetomidine for lumbar spinal surgery (MD, -0.81; 95% CI, -1.24, -0.35; p = 0.0005). In the case of lumbar spinal operations, the addition of dexmedetomidine to the postoperative treatment resulted in a marked reduction in the pain at 24 h post-operation (MD, -0.64; 95% CI, -0.79, -0.48; p < 0.0001). The quality of the data we evaluated was 'moderate' to 'good'; thus, we have limited confidence in the impact estimation, and the actual impact might be significantly different from what we had expected. Additional studies should concentrate on practices that are well known to cause severe postoperative pain, especially for cases where the improvement of pain management may lead to substantial clinical benefits in terms of reduction of morbidity or cost-effectiveness in terms of quicker healing and release.
FIELD: medicine, ophthalmology. SUBSTANCE: method involves radical polymerization of monomers of acryl and/or vinyl order in the presence of water and cross-linking agent. Fibronectin or chemically modified fibronectin in concentration 0.02-4.0 mg/ml is added to mixture to be polymerized and polymerization is carried out by irradiation or by substantial initiation. Invention can be used for making intracorneal lens and implants, keratoprosthesis and artificial irides. EFFECT: decreased complications associated with excessive scarring and transparency loss of eye optical media in implant zone. 3 cl, 4 ex
This study was conducted from 2018 to 2020. This study included patients who were with presence of cataract in both eyes, age between 50 and 80 years, and corrected distance visual acuity (CDVA) of both eyes under 20/40. Phacoemulsification cataract surgery was arranged for both eyes for all patients. The study groups of IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA). The patients were routinely examined preoperatively as well as 1 month after surgery for far and near visual acuity (in LogMAR unit). Contrast sensitivity, wavefront aberration and quality of vision questionnaire was measured at the 1-month postoperative visit. These aforementioned outcomes were recorded and compared between groups.
PURPOSE: To obtain the subject material comprising a carrier in the form of fibrous material and a specific proportion of enzyme immobilized thereon, useful for treating trauma, frostbite, suppurative necrotic wound, etc., and preservable over a long period. CONSTITUTION: This biologically active material comprises 99.50-99.98wt.% of a carrier in the form of fibrous material and 0.02-0.50wt.% of an enzyme (e.g. protease, collagenase, lytic enzyme) immobilized on and covalently bound to the carrier. This material is produced by the following process: reactive functional group at 0.0625-3.125g eq. per g of the fibrous material is formed in the fibrous material, an enzyme is then immobilized on the fibrous material through its buffer solution at pH6.5-7.5 at room temperature for 8-12h so as to form covalent bond between the enzyme and the fibrous material. The above fibrous material is e.g. woven fabric, nonwoven fabric, knit fabric, lint 1.0-15mm in fiber length, powder 0.001-1.0mm in particle size.
Cognitive training intervention. The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The experimental group will receive real-world strategy training, a cognitive strategy based approach that trains people to improve their level of independence on meaningful activities of daily life with which they are having difficulty.
1382435 Free-flowing epicillin M D WARD 22 Nov 1971 54162/71 Heading C2C [Also in Division A5] A novel free-flowing form of α-amino-(1,4- cyclohexadienyl) methylpenicillin (epicillin) is prepared by precipitating this substance from an acidic aqueous solution thereof containing 0À1 to 1À0% wt./vol. of a cationic surface active agent by addition of a base. The epicillin in its usual needle-like crystalline form is dissolved in water acidified to below pH 2À0 (preferably about pH 1À5) with a strong mineral acid, e.g. H 2 SO 4 , at a temperature of about 0-5 C. Cationic surface active agent, preferably in aqueous solution at about 0-5 C., is added to the epicillin solution to a final concentration of 0À1 to 1% wt./vol., preferably about 1% wt.-vol. The surface active agent may be a mixed alkyl or alkylaralkyl quaternary ammonium halide, e.g. tetradecyltrimethylammonium bromide or benzalkonium chloride, or a quaternary salt of a heterocyclic amine, e.g. cetyl pyridinium chloride. The base, preferably 5N aqueous sodium hydroxide, is then added at about 15-20 C. to bring the pH to about 4À0, when the epicillin precipitates in a platelet or cubical crystalline form which is separated, washed and dried.
FIELD: food industry. ^ SUBSTANCE: invention is referred to feeding stuff production. Composition for fatty tissue dissimilation speed-up, fatty acids oxidation speed-up or reduce of fatty tissue dissimilation contains one or more isoflavones or its metabolites and conjugated linoleic acid (CLA) or/and L-carnitine. All components are taken in certain daily quantity. Composition is used to keep animal's muscle bulk, to reduce tissue injury connected to adiposity. ^ EFFECT: invention allows to obtain composition which can promote reduce of fat depots, reduce muscle bulk losses and reduce injuries related to oxidative stress. ^ 35 cl, 12 dwg, 2 ex
The current proposal is to conduct a study using a battery of neuropsychological tests capable of detecting the broad range of cognitive difficulties associated with relapsing remitting multiple sclerosis. This study will compare cognitive functioning over time of patients receiving alemtuzumab. The study will also compare the change in cognitive functioning over time to that of relapsing remitting multiple sclerosis patients receiving interferon beta-1a and normal controls enrolled in a parallel study conducted by Wilken et al.To evaluate cognitive effects of alemtuzumab, the investigators will perform neurological exams and brain scans and will administer questionnaires to measure the severity of multiple sclerosis, how well subjects are functioning, how they are feeling, and to find out about what other medical visits subjects may have had during the study. Neurological testing in this study will require the subject to perform relatively simple tasks to evaluate their multiple sclerosis. These tasks include a five hundred meter walk, a timed twenty five foot walk, a nine hole peg test, an eye exam, and a test requiring you to add small numbers in your head quickly. The brain scans will involve Magnetic Resonance Imaging and are painless, except for injection of a contrast agent called gadolinium, which is necessary to detect areas in the brain where their MS may be currently active. Magnetic Resonance Imaging is widely used to diagnose and assess patients with multiple sclerosis. All patients will be required to return to their study site every 3 months for assessments and testing. In addition, safety-related blood tests will be performed at least monthly. If their blood test results become abnormal, they may have to have blood tests taken more frequently, in some cases weekly, until test results improve. Monthly blood tests should be performed at your study site, but if subjects are unable to return to the study site for the blood testing, they may be able to use a local laboratory.

Participation in this study should last at least 4 years and possibly longer.

Subjects receiving alemtuzumab, will need to have blood tests every month for at least 3 years after your last dose of alemtuzumab. Therefore, you will need to undergo monthly blood tests for a total of about 4 years. If your test results become abnormal, you may have to have blood tests more frequently, in some cases weekly, until your test results improve.
Paclitaxel injection must be diluted prior to infusion. Paclitaxel injection should be diluted in 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer’s Injection to a final concentration of 0.3 to 1.2 mg/mL. The solutions are physically and chemically stable for up to 27 hours at ambient temperature (approximately 25°C) and room lighting conditions. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Upon preparation, solutions may show haziness, which is attributed to the formulation vehicle. No significant losses in potency have been noted following simulated delivery of the solution through IV tubing containing an in-line (0.22 micron) filter.

Data collected for the presence of the extractable plasticizer DEHP [di-(2-ethylhexyl)phthalate] show that levels increase with time and concentration when dilutions are prepared in PVC containers. Consequently, the use of plasticized PVC containers and administration sets is not recommended. Paclitaxel injection solutions should be prepared and stored in glass, polypropylene, or polyolefin containers. Non-PVC containing administration sets, such as those which are polyethylene-lined, should be used.

Paclitaxel injection should be administered through an in-line filter with a microporous membrane not greater than 0.22 microns. Use of filter devices such as IVEX-2® filters which incorporate short inlet and outlet PVC-coated tubing has not resulted in significant leaching of DEHP.

The Chemo Dispensing Pin™ device or similar devices with spikes should not be used with vials of paclitaxel injection since they can cause the stopper to collapse resulting in loss of sterile integrity of the paclitaxel injection solution.
FIELD: medicine, ophthalmology, pharmacy. SUBSTANCE: composition comprises, wt.%: topical short-acting anesthetics, 0.01-5.0; topical long-acting anesthetics, 0.01-5.0; buffer isotonic solution, pH 6.8-7.6, the balance. The composition can comprise additionally heparin, mydriatic drug, adrenomimetic drug, carnosine, steroid and nonsteroid anti-inflammatory agents, antihemorrhagic and hemostatic agents taken in indicated doses. Invention ensures to attain the effective and prolonged anesthetization during total surgery (diagnostic) procedure and in early postoperative period. Invention can be used in cavity ophthalmic operations for prolonged intrachamber anesthesia and analgesia in sutures removing, nonpenetrating deep sclerotomy, diagnostic manipulations on an anterior eye segment and others. EFFECT: enhanced efficiency of composition. 10 cl, 7 ex
In condition #2, the facilitator will perform a standard hypnotic short induction followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the clinician read a standardized hypnotic script that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
ARFI measurements of the spleen will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
General: Initial doses higher than 1 mg may produce orthostatic hypotension. Care should be exercised when administering cabergoline with other medications known to lower blood pressure.

Postpartum Lactation Inhibition or Suppression: Cabergoline is not indicated for the inhibition or suppression of physiologic lactation. Use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of hypertension, stroke, and seizures.

Hepatic Impairment: Since cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering cabergoline to patients with hepatic impairment.

Psychiatric: Impulse control/compulsive behaviors, including pathological gambling, increased libido, and hypersexuality have been reported in patients treated with dopamine agonists including cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation (see Post-marketing Surveillance data). Prescribers should consider dose reduction or stopping the medication if a patient develops such urges while taking cabergoline.